Glucocorticoids mediate fasting efficacy in breast cancer.
1/5 보강
Addressing endocrine resistance in hormone receptor-positive breast cancer, Padrão et al.
APA
Li A, Huang H, Xiang R (2026). Glucocorticoids mediate fasting efficacy in breast cancer.. Trends in endocrinology and metabolism: TEM. https://doi.org/10.1016/j.tem.2026.02.001
MLA
Li A, et al.. "Glucocorticoids mediate fasting efficacy in breast cancer.." Trends in endocrinology and metabolism: TEM, 2026.
PMID
41820091 ↗
Abstract 한글 요약
Addressing endocrine resistance in hormone receptor-positive breast cancer, Padrão et al. identify the glucocorticoid receptor (GR) as the key transducer of fasting benefits. They demonstrate that pharmacological GR activation recapitulates antitumor efficacy, offering a targeted therapeutic avenue that avoids the challenges of rigorous dieting.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Automated quantification of tumor-infiltrating lymphocytes by machine learning reveals prognostic and immunogenomic features in lung cancer.
- Immune-related LncRNA signatures define tumor microenvironment subtypes and predict immunotherapy response in NSCLC.
- Occult obstructive sleep apnea in survivors of Hodgkin lymphoma following radiation therapy: an atypical and under-recognized phenotype.
- Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
- Multi-omics analysis identifies TLRscore for prognostic prediction and highlights TLR8 in macrophage-mediated antitumor immunity of lung adenocarcinoma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The role of Notch signalling and its crosstalk with oestrogen receptor signalling in breast cancer.
- Sodium valproate drives propionylation-mediated epigenetic reprogramming to enhance mesothelin CAR-T cell therapy in solid tumors.
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.
- Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER+HER2- Breast Cancer.
- Integrated multi-omics analysis reveals comprehensive metabolism-driven tumor heterogeneity and immune microenvironment in hepatocellular carcinomas.
- The natural L370F ERα variant confers endocrine resistance and sensitivity to ATRA in metastatic breast cancer cells.